Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Allogene Therapeutics (ALLO) EBT: 2018-2024

Historic EBT for Allogene Therapeutics (ALLO) over the last 7 years, with Dec 2024 value amounting to -$257.1 million.

  • Allogene Therapeutics' EBT rose 36.60% to -$41.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$209.6 million, marking a year-over-year increase of 23.65%. This contributed to the annual value of -$257.1 million for FY2024, which is 21.43% up from last year.
  • Latest data reveals that Allogene Therapeutics reported EBT of -$257.1 million as of FY2024, which was up 21.43% from -$327.3 million recorded in FY2023.
  • In the past 5 years, Allogene Therapeutics' EBT ranged from a high of -$250.2 million in FY2020 and a low of -$331.0 million during FY2022.
  • Its 3-year average for EBT is -$305.1 million, with a median of -$327.3 million in 2023.
  • As far as peak fluctuations go, Allogene Therapeutics' EBT crashed by 35.31% in 2020, and later rose by 21.43% in 2024.
  • Allogene Therapeutics' EBT (Yearly) stood at -$250.2 million in 2020, then fell by 2.71% to -$257.0 million in 2021, then dropped by 28.78% to -$331.0 million in 2022, then rose by 1.12% to -$327.3 million in 2023, then rose by 21.43% to -$257.1 million in 2024.